Lilly’s Alzheimer’s drug may slow patients’ decline, study shows By: MarketWatch July 22, 2015 at 07:23 AM EDT Eli Lilly’s Alzheimer’s treatment, solanezumab, can slow the decline of memory and function, a study shows. Read More >> Related Stocks: Biogen Idec Eli Lilly